SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

Xolair is a branded injectable medication used to treat allergic asthma, chronic hives, and rhinosinusitis. It’s recently been approved to manage food allergies, reducing the risk of serious reactions ...

XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks. In people with asthma, CRSwNP and food allergy, a blood test for a substance called IgE must be ...

The U.S. Food and Drug Administration (FDA) has approved a medication for use in treating severe food allergies, and the agency says that this injection is the first of its kind. The drug, which has ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted, under ...

A new drug could let those with severe food allergies breathe a sigh of relief. Xolair, or omalizumab, was granted priority review by the Food and Drug Administration on Tuesday for its use in ...

The drug does not completely prevent reactions, but it can reduce the risks posed by trace amounts of food allergens. By Roni Caryn Rabin The Food and Drug Administration approved a drug this month ...

A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. Data ...

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure Interim analysis results from first-of-its-kind phase III OUtMATCH study ...

The injection is the first of its kind. Getty The U.S. Food and Drug Administration (FDA) has approved a medication for use in treating severe food allergies, and the agency says that this injection ...

Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate ...